

# Can Chemical Mouthwash Agents Achieve Plaque/ Gingivitis Control?



Fridus A. Van der Weijden, PhD<sup>a,\*</sup>, Eveline Van der Sluijs, Msc<sup>a</sup>, Sebastian G. Ciancio, DDS<sup>b</sup>, Dagmar E. Slot, Msc, PhD<sup>a</sup>

#### **KEYWORDS**

- Dental plaque
   Gingivitis
   Mouthwash
   Mouthrinse
   Systematic review
- Meta-review

#### **KEY POINTS**

- Oral health is important since the mouth is the gateway to the human body. Bacteria are always present in the oral cavity and when not frequently removed the dental plaque biofilm leads to the development of oral disease.
- Over the past decades, the use of mouthwashes has become customary, usually following mechanical plaque biofilm control.
- Although people in industrialized countries use various oral hygiene products with the
  expectation of an oral health benefit, it is important that sufficient scientific evidence exists
  to support such claims.
- This meta-review summarized and appraised the current state of evidence that was based
  on systematic reviews, with respect to the efficacy of various active ingredients of overthe-counter chemotherapeutic mouthwash formulations for plaque control and managing
  gingivitis.
- Evidence suggests that a mouthwash containing chlorhexidine (CHX) is the first choice.
   The most reliable alternative for plaque control is essential oil (EO). No difference between CHX and EO with respect to gingivitis was observed.

Conflict of Interest and Source of Funding Statement: The authors declare that they have no conflict of interest. This study was self-funded by the authors and their institutions. Ethical approval was not required. D.E. Slot and F.A. Van der Weijden have formerly received external advisor fees, lecturer fees, or research grants from companies that produce mouthwash products. Among these were Colgate, Dentaid, GABA, Lactona, Oral-B, Philips, Procter & Gamble, Sara Lee, Sunstar, and Unilever. Similarly, S.G. Ciancio has interacted with Colgate, Johnson & Johnson, St. Renatus, Phoenix Dental, and Sunstar.

- <sup>a</sup> Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam, VU University Amsterdam, Amsterdam, The Netherlands; <sup>b</sup> Department of Periodontics and Endodontics, University at Buffalo, The State University of New York, Buffalo, NY, USA
- \* Corresponding author. Academic Centre for Dentistry Amsterdam (ACTA), Department of Periodontology, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands. E-mail address: ga.vd.weijden@acta.nl

Dent Clin N Am 59 (2015) 799-829

#### INTRODUCTION

The need to prevent human disease is well recognized and is related to making the occurrence or progression of a disease process unlikely or impossible. Oral health is important because the mouth is the gateway to the human body. Bacteria are always present in the oral cavity and when not frequently removed, the dental plaque biofilm leads to the development of oral disease. The merits of daily oral hygiene to oral health have long been understood. Studies of tooth cleaning suggest that despite technological innovations, the level of mechanical oral hygiene practice is inadequate.

The principle that plaque biofilm is the major etiologic factor causing gingivitis provides the justification for the use of antimicrobial mouth rinses.<sup>5</sup> The practice of mouth rinsing has been in use by humans for more than 2000 years. The first mouthwash advocated for dental plaque reduction seems to be urine from a child or, even better, from a newborn baby.<sup>6</sup> In the 1880s, Willoughby D. Miller (a dentist trained in microbiology) was the first to suggest the use of an antimicrobial mouthwash containing phenolic compounds to combat gingival inflammation.<sup>7</sup> Over the past decades, the use of mouthwashes has become customary, usually following mechanical plaque biofilm control. Mouthwashes are an ideal vehicle in which to incorporate chemicals and are appreciated by the public because of their ease of use, reduction of plaque biofilm, and breath-freshening effect.<sup>8–10</sup>

With keen competition between individual manufacturers vying for a percentage of this market, various claims for efficacy have been made, using numerous terms to describe efficacy. Although people in industrialized countries use various oral hygiene products with the expectation of an oral health benefit, it is important that sufficient scientific evidence exists to support such claims. Dental professionals have choices and make decisions every day as they advise their patients. 11 An evidence-based clinical decision integrates and concisely summarizes all relevant and important research evidence of acceptable quality that examines the same therapeutic question. The model to guide clinical decisions begins with original single random controlled clinical studies at its foundation. Syntheses (systematic reviews) build up from these to integrate the best available evidence from these original studies. 12 At the next level, a synopsis summarizes the findings of high-quality systematic reviews. 13,14 Meta-analyses (meta-review) in particular are appropriate for describing whether the current evidence base is complete or incomplete. The quantitative evidence is synthesized from relevant previous systematic reviews. The reason for including only systematic reviews is because this kind of research generally provides more evidence than separate empirical studies. Also in the presence of a significant increase in systematic reviews, meta-reviews give the dental community better guidance. From this perspective, it is a step forward in the direction of a clinical guideline. 15,16 Meta-reviews are a tool, a form of information, and guidance based on research evidence that assists the clinician in formulating the answer appropriate for each individual patient.<sup>11</sup>

Recently, 2 meta-reviews have been published that evaluate the efficacy of home-care regimens for mechanical plaque removal (toothbrushes and interdental cleaning devices) on plaque and gingivitis in adults.<sup>2,3</sup> The purpose of this article was to prepare a meta-review that summarizes the contemporary synthesized evidence with respect to the efficacy and safety of home-care self-support activities focusing on chemical agents in mouthwashes to manage plaque and gingivitis.

#### MATERIALS AND METHODS

The protocol of this meta-review detailing the evaluation method was developed using the AMSTAR<sup>17</sup> (a measurement tool to assess systematic reviews) tool to ensure the methodological quality of the review process.

# **Focused Question**

What is the effect of mouthwashes and their various chemical ingredients for plaque biofilm control in managing gingivitis in adults based on evidence gathered from existing systematic reviews?

# Search Strategy

For the comprehensive search strategy, several electronic databases were queried. Three Internet sources were used to search for appropriate articles that satisfied the study purpose. These sources included the National Library of Medicine, Washington, DC (MEDLINE-PubMed), the Cochrane Library, which also includes the DARE database of systematic reviews, and the evidence database of the American Dental Association (ADA) Center for Evidence-based Dentistry. All 3 databases were searched for eligible studies up to and including February 2015. The structured search strategy was designed to include any systematic review published on mouthwash products. For details regarding the search terms used, see Box 1. All of the reference lists of the selected studies were hand-searched for additional published work that could possibly meet the eligibility criteria of the study. The PROSPERO (2014) database, an international database of prospectively registered systematic reviews, was checked for reviews in progress. Further unpublished work was not sought.

#### Screening and Selection

Two reviewers (DES and EvdS) independently screened the titles and abstracts for eligible articles. If eligibility aspects were present in the title, the article was selected for further reading. If none of the eligibility aspects were mentioned in the title, the abstract was read in detail to screen for suitability. Inclusion of titles, abstracts, and ultimately full texts was based initially on full agreement between the 2 reviewers (DES and EvdS). In case of discrepancies, the final decision was made following discussion with GAW. No attempt was made to blind the reviewers to names of authors or institutions and journals while making the assessment. Hand searching of reference lists of reviews was conducted to ensure inclusion of additional published and potentially

#### Box 1

Search terms used for PubMed-MEDLINE, Cochrane Library, and American Dental Association Center for Evidence-based Dentistry

The search strategy was customized appropriately according to the database being searched, taking into account differences in controlled vocabulary and syntax rules.

The following strategy was used in the search mouthwashes:

{[MeSH Terms] Mouthwashes OR [text words] Mouthwashes OR Mouthwash OR mouthwash\* OR mouthrinses OR mouthrinse}

Used filter/limits: systematic review OR meta-analysis

\* Used as a truncation symbol.

relevant articles. When updates of systematic reviews were published, the latest version was selected. At the outset of this meta-review, no attempt was made to separate specific variables associated with mouthwashes.

#### Inclusion and Exclusion Criteria

The inclusion criteria were as follows:

- Systematic reviews (with or without a meta-analysis)
- Articles written in the English or Dutch language
- Reviews evaluating studies conducted on humans
  - >18 years old
  - o In good general health
- Intervention: mouthwashes and their various chemical ingredients for plaque control and reducing gingivitis

The exclusion criteria were as follows:

- Orthodontic patients
- Dental implants

# Data Extraction and Assessment of Heterogeneity

The articles that fulfilled all of the selection criteria were processed for data extraction. Information extracted from the studies included publication details, focused questions, search results, descriptive or meta-analysis outcomes, and conclusions. Systematic reviews were categorized by 2 authors (DES and EvdS) according to various active ingredients of mouthwashes. Categorization was confirmed with a second author (GAW). Disagreements between the reviewers were resolved by discussion.

The heterogeneity across studies was detailed according to the following factors:

- Study and subject characteristics
- Methodological heterogeneity (variability in review approach and risk of bias)
- Analysis performed (descriptive or meta-analysis)

Heterogeneity within the meta-analysis was tested by  $\chi^2$  test and the  $I^2$  statistical. A  $\chi^2$  test resulting in a P<.1 was considered an indication of significant statistical heterogeneity. As a rough guide for assessing the possible magnitude of inconsistency across studies, an  $I^2$  statistic of 0% to 40% was interpreted as not being important, and with an  $I^2$  statistic higher than 40%, moderate (40%–80%) to considerable (>80%) heterogeneity may be present. <sup>18</sup>

# **Quality Assessment**

Two reviewers (DES and EvdS) estimated the risk of bias by scoring the reporting and methodological quality of the included systematic reviews according to a combination of items described by the PRISMA<sup>19</sup> guideline for reporting systematic reviews and the<sup>17</sup> checklist for assessing the methodological quality of systematic reviews. A list of 27 items was assessed, and if all individual items were given a positive rating by summing these items, an overall score of 100% was obtained. Only systematic reviews including meta-analysis could achieve a full score of 100%.<sup>20</sup> The estimated risk of bias was interpreted as follows: 0% to 40% may represent a high risk of bias, 40% to 60% may represent a substantial risk of bias, 60% to

80% may represent a moderate risk of bias, and 80%-100% may represent a low risk of bias.<sup>3</sup>

# Grading the 'Body of Evidence'

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, as proposed by the GRADE working group, was used to grade the evidence emerging from this meta-review of systematic reviews. <sup>21</sup> Two reviewers (DES and GAW) rated the quality of the evidence as well as the strength of the recommendations according to the following aspects: study design, risk of bias, consistency and precision among outcomes, directness of results, detection of publication bias, and magnitude of the effect.

# RESULTS

# Search and Selection Results

**Fig. 1** describes the search process. A total of 306 unique articles were identified, from which 17 full-text articles were obtained and screened to confirm eligibility. One study was excluded because the data were summarized for a large variety of natural compounds and did not allow for an evaluation of individual ingredients. <sup>22</sup> Hand searching of the reference lists from these articles did not reveal any additional suitable systematic reviews. Neither did a search of the PROSPERO (International Prospective Register of Systematic Reviews) database (2014). Two papers by Gunsolley<sup>23,24</sup> provided data on the same meta-analysis. As a result, a final 15 systematic reviews were identified as being eligible for inclusion in this synopsis. Nine articles were identified that evaluated the efficacy of single active ingredients, of which 2 reviewed more than 1 ingredient. <sup>23,24,26</sup> Five studies compared active ingredients, of which 2 also contributed data for the singles active ingredients. <sup>27,28</sup> In one publication, a combination of 2 active ingredients was systematically evaluated. <sup>29</sup>

#### Study Outcomes and Assessment of Heterogeneity

Considerable heterogeneity was observed in the 15 systematic reviews with respect to the data bases searched, study and subject characteristics of the original individual articles, description of inclusion and exclusion criteria, quality assessment scale used, reporting of effect scores, presence of meta-analysis, and conclusions made. Because of this heterogeneity, a sophisticated level of data combination and analysis was neither possible nor indicated. A meta-analysis was therefore not undertaken. For the purpose of this synopsis, a summary of the selected systematic reviews was categorized and is presented by various chemical ingredients and ordered by common characteristics in Table 1.

#### **Quality Assessment**

Most reviews were considered to have a low to moderate estimated risk of bias (**Table 2**). Two studies were estimated to have a substantial risk of bias.<sup>23–25</sup> Critical items in this evaluation were the development of a protocol "a priori" and its registration, including non-English literature, contacting authors for additional information, grading obtained evidence, and the assessment of publication bias.

#### Active Ingredients

For details regarding the extracted data of the meta-analysis, difference of means, *P* values, 95% confidence intervals, and test of heterogeneity, please see **Table 3** for Plaque Index scores and **Table 4** for Gingival Index scores.




Fig. 1. Search and selection results.

#### Single Active Ingredients

#### Alexidine

Alexidine (ALX) is an antimicrobial of the biguanide class, and contains ethylhexyl end groups. This structure favors hydrophobic penetration into membrane lipids and electrostatic adhesion to the negative sites of cell membranes resulting in bactericidal activity. The systematic review by Serrano and colleagues<sup>26</sup> identified 2 articles and evaluated the adjunctive effect of ALX to toothbrushing in the prevention of plaque accumulation and gingival inflammation in studies with duration of 6 months or longer. The study outcome with respect to the Quigley and Hein<sup>36</sup> Plaque Index (PI) scores at the conclusion of the individual studies demonstrated a significant difference of means (DiffM) of -0.16, with nonsignificant heterogeneity ( $I^2 = 39.5\%$ ). Data with respect to

| Author, (Year),<br>Ingredient  | Databases Searched  | No. of Included Studies/<br>Trails, No. Involved<br>Participants Base (End) | Leading Mode<br>of Analysis | Original Review Authors'<br>Conclusions   | Comments of the Meta-<br>Review Authors  |
|--|---|---|-----------------------------|---|--|
| Serrano et al, <sup>26</sup><br>2015<br>Multiple<br>ingredients                            | • PubMed  | ? studies<br>? (?)  | Meta-analysis               | Formulations with specific agents for chemical plaque control provide statistically significant improvements in terms of gingival bleeding and plaque indices.  | TCL was assessed in the meta<br>analysis as a "pre-rinse" toothbrushing, which is<br>considered to provide an<br>"indirect" effect because<br>this is not a common dail<br>oral hygiene habit. |
| Van Leeuwen<br>et al, <sup>30</sup> 2014<br>EO   | <ul><li>PubMed-Medline</li><li>Cochrane-CENTRAL</li><li>EMBASE</li></ul>  | 5 studies<br>605 (534)  | Meta-analysis               | EOs produce an effect on plaque and gingivitis that extends beyond the vehicle solution.  | Comparisons with vehicle control are frequently done with 5% hydroalcohol, whereas a true placebo would contain 21.6%–26.9% alcohol.   |
| Van Maanen-<br>Schakel et al, <sup>29</sup><br>2012<br>CHX + H <sub>2</sub> O <sub>2</sub> | <ul><li>PubMed-Medline</li><li>Cochrane-CENTRAL</li><li>EMBASE</li><li>Trial registers</li><li>Others</li></ul> | 4 studies<br>252 (229)  | Meta-analysis               | There is moderate evidence that a combination of CHX and an OA reduces tooth staining without interfering with plaque growth inhibition.  | Tooth discoloration was considered as the primary outcome variable and plaque and gingivitis as secondary.   |
| Van Strydonck<br>et al, <sup>18</sup> 2012<br>CHX  | <ul><li>PubMed-Medline</li><li>Cochrane-CENTRAL</li><li>EMBASE</li></ul>  | 30 studies<br>34 experiments<br>3554 (2965)                                 | Meta-analysis               | There is strong evidence for the antiplaque and antigingivitis effects of a CHX rinse as an adjunct to regular oral hygiene in gingivitis patients; however, a significant increase in staining score was seen by CHX mouthrinse. | Staining as a side effect of<br>CHX can affect patient<br>compliance.  |

| Author, (Year),<br>Ingredient  | Databases Searched   | No. of Included Studies/<br>Trails, No. Involved<br>Participants Base (End) | Leading Mode<br>of Analysis | Original Review Authors'<br>Conclusions   | Comments of the Meta-<br>Review Authors  |
|--|--|---|-----------------------------|---|--|
| Van Leeuwen<br>et al, <sup>31</sup> 2011<br>EO vs CHX                    | <ul><li>PubMed-Medline</li><li>Cochrane</li></ul>                            | 19 studies<br>827 (?)   | Meta-analysis               | Long-term studies showed that CHX mouthwash was statistically more effective than EO with respect to plaque control; however, there was no significant difference with respect to reduction of gingival inflammation. Also, significantly more staining was observed with CHX compared with EO. | The evidence suggests that EO acts primarily through an anti-inflammatory process and is a reliable alternative to CHX for long-term control of gingival inflammation. |
| Hossainian<br>et al, <sup>28</sup> 2011<br>H <sub>2</sub> O <sub>2</sub> | <ul> <li>PubMed-Medline</li> <li>Cochrane-CENTRAL</li> <li>EMBASE</li> </ul> | 10 studies<br>12 experiments<br>384 (363)                                   | Descriptive<br>analysis     | H <sub>2</sub> O <sub>2</sub> mouthwashes do not consistently prevent plaque accumulation when used as a short-term monotherapy. When used as a long-term adjunct to daily oral hygiene, the results of one study indicate that oxygenating mouthwashes reduce gingival redness.                | A side effect of painful<br>sensation in the mouth<br>and/or erosive changes of<br>the oral mucosa may occu  |
| Gunsolley, <sup>23,24</sup><br>2006, 2010<br>Multiple<br>ingredients     | <ul><li>Medline</li><li>Unpublished studies</li></ul>                        | ? studies<br>? (?)  | Meta-analysis               | The studies provide strong evidence of the antiplaque and antigingivitis effects of multiple agents. It supports the use of mouthwashes as part of a daily oral hygiene.  | The review methodology is unclear.   |

| Afennich et al, <sup>27</sup><br>2011<br>HEX                  | <ul><li>PubMed-Medline</li><li>Cochrane- CENTRAL</li><li>EMBASE</li></ul> | 6 studies<br>357 (336)                 | Descriptive<br>analysis        | HEX mouthwashes provide<br>better effects regarding<br>plaque reduction than<br>placebo mouthwashes.<br>They are less effective than<br>CHX.  | Higher HEX concentrations cause more side effects compared with lower concentrations.  |
|---|---|--|--------------------------------|---|--|
| Berchier et al, <sup>32</sup><br>2010<br>CHX<br>0.12% vs 0.2% | <ul><li>PubMed-Medline</li><li>Cochrane</li></ul>                         | 8 studies<br>10 experiments<br>803 (?) | Meta-analysis                  | In the comparison, 0.12% and 0.2% CHX information concerning the effect on gingival inflammation was sparse. With respect to plaque inhibition, the results showed a small but significant difference in favor of the 0.2% CHX concentration. | The clinical relevance of the difference between the 2 concentrations was considered negligible. Several subanalyses are performed, such as rinsing duration, mouthwash solution with/without alcohol, manufacturer. |
| Haps et al, <sup>33</sup><br>2008<br>CPC                      | <ul><li>PubMed-Medline</li><li>Cochrane</li></ul>                         | 8 studies<br>867 (?)                   | Meta-analysis                  | When used as an adjunct to either supervised or unsupervised oral hygiene, CPC-containing mouth rinses provide a small but significant additional benefit in reducing plaque accumulation and gingival inflammation.                          | The bioavailability and concentration of the active ingredient may influence its clinical efficacy.  |
| Addy et al, <sup>25</sup><br>2007<br>DEL                      | • Unknown   | 8 studies<br>913 (?)                   | Pooled weighted point estimate | DEL is effective as an adjunct<br>measure for reducing<br>plaque burden and indices<br>of gingivitis, whether or<br>not it is used under<br>supervision.  | No common method for meta-analysis was used.   |
|   |   |  |                                |   | (continued on next page)   |

| Table 1<br>(continued)  |  |   |                             |  |  |
|---|--|---|-----------------------------|--|--|
| Author, (Year),<br>Ingredient   | Databases Searched   | No. of Included Studies/<br>Trails, No. Involved<br>Participants Base (End) | Leading Mode<br>of Analysis | Original Review Authors'<br>Conclusions  | Comments of the Meta-<br>Review Authors  |
| Stoeken et al, <sup>34</sup><br>2007<br>EO                                    | <ul><li>PubMed-Medline</li><li>Cochrane</li></ul>                        | 11 studies<br>2810 (2515)   | Meta-analysis               | EO provides an additional benefit to unsupervised oral hygiene with regard to plaque and gingivitis reduction as compared with a placebo or control. | Comparisons are also made<br>to 5% hydro-alcohol, CHX<br>and a group that uses floss.                            |
| Paraskevas &<br>van der<br>Weijden, <sup>35</sup><br>2006<br>SnF <sub>2</sub> | <ul><li>PubMed-Medline</li><li>Cochrane-CENTRAL</li><li>EMBASE</li></ul> | 3 studies concerning<br>mouthwashes<br>781 (500)                            | Descriptive<br>analysis     | With regard to SnF <sub>2</sub> , there is insufficient information on gingivitis and plaque to make any conclusions.                                | The effect of the combined use of SnF <sub>2</sub> dentifrice + SnF <sub>2</sub> mouthwash would be of interest. |

Abbreviations: ?, unknown; CHX, chlorhexidine; CPC, cetylpyridinium chloride; DEL, delmopinol; EO, essential oils;  $H_2O_2$ , hydrogen peroxide; HEX, hexetidine; OA, oxygenating agents;  $SnF_2$ , stannous fluoride; TCL, triclosan.

| Table 2<br>Estimated the risk                           | k of bias                         | by scoring a l                        | list of items                         | related to th                             | ie reporting          | and method                  | lological quali  | ity of th                            | ie inclu                 | ded syst                     | tematic reviev               | ws  |  |
|---|-----------------------------------|---------------------------------------|---------------------------------------|---|-----------------------|-----------------------------|--|--------------------------------------|--------------------------|------------------------------|------------------------------|---|--|
| Author,<br>Criteria                                     | Addy et al, <sup>25</sup><br>2007 | Afennich et al, <sup>77</sup><br>2010 | Berchier et al, <sup>32</sup><br>2010 | Gunsolley, <sup>23,24</sup><br>2006, 2010 | Haps et al,³³<br>2008 | Hossainian et al,²8<br>2011 | Paraskevas &<br>van der Weijden, <sup>35</sup><br>2006 | Serrano et al, <sup>26</sup><br>2015 | Stoeken et al,³4<br>2007 | Van Leeuwen et al,³1<br>2011 | Van Leeuwen et al,³0<br>2014 | Van Maanen-<br>Schakel et al, <sup>29</sup><br>2012 | Van Strydonck et al, <sup>18</sup><br>2012 |
| Defined<br>outcome<br>criteria of<br>interest           | +                                 | +                                     | +                                     | +   | +                     | +                           | +  | +                                    | +                        | +                            | +                            | +   | +  |
| Describes the rationale                                 | +                                 | +                                     | +                                     | +   | +                     | +                           | +  | +                                    | +                        | +                            | +                            | +   | +  |
| Describes the focused (PICO) [S] question/hypothesis    | +                                 | +                                     | +                                     | +   | +                     | +                           | +  | +                                    | +                        | +                            | +                            | +   | +  |
| Describes if a protocol was developed "a priori"        | _                                 | -                                     | _                                     | -   | _                     | _                           | _  | +                                    | _                        | _                            | -                            | -   | _  |
| Protocol<br>registration/<br>publication                | _                                 | _                                     | _                                     | _   | -                     | -                           | _  | ?                                    | -                        | -                            | -                            | -   | _  |
| Presented eligibility criteria (in/ exclusion criteria) | +                                 | +                                     | +                                     | +   | +                     | +                           | +  | +                                    | +                        | +                            | +                            | +   | +  |
| ı   |                                   |                                       |                                       |   |                       |                             |  |                                      |                          |                              | (cc                          | ontinued on r                                       | next page)                                 |

| Table 2<br>(continued)  |                                   |                                       |                                       |   |                                   |   |  |                                      |                                      |                              |  |   |  |
|---|-----------------------------------|---------------------------------------|---------------------------------------|---|-----------------------------------|---|--|--------------------------------------|--------------------------------------|------------------------------|--|---|--|
| Author,<br>Criteria   | Addy et al, <sup>25</sup><br>2007 | Afennich et al, <sup>27</sup><br>2010 | Berchier et al, <sup>32</sup><br>2010 | Gunsolley, <sup>23,24</sup><br>2006, 2010 | Haps et al, <sup>33</sup><br>2008 | Hossainian et al, <sup>28</sup><br>2011 | Paraskevas &<br>van der Weijden, <sup>35</sup><br>2006 | Serrano et al, <sup>26</sup><br>2015 | Stoeken et al, <sup>34</sup><br>2007 | Van Leeuwen et al,³¹<br>2011 | Van Leeuwen et al, <sup>30</sup><br>2014 | Van Maanen-<br>Schakel et al, <sup>29</sup><br>2012 | Van Strydonck et al, <sup>18</sup><br>2012 |
| Presents the full search strategy   | _                                 | +                                     | +                                     | +   | +                                 | +                                       | +  | _                                    | +                                    | +                            | +  | +   | +  |
| Various<br>databases<br>searched  | ?                                 | +                                     | +                                     | _   | +                                 | +                                       | +  | +                                    | +                                    | +                            | +  | +   | +  |
| Performed<br>(hand) search<br>in additional<br>sources (f.i.<br>grey literature<br>or trial<br>registers) | ?                                 | +                                     | +                                     | -   | +                                 | +                                       | _  | +                                    | +                                    | +                            | +  | +   | +  |
| Review selection<br>by more than 1<br>reviewer  | _                                 | +                                     | +                                     | +   | +                                 | +                                       | +  | +                                    | +                                    | +                            | +  | +   | +  |
| Non-English<br>articles<br>included   | ?                                 | _                                     | -                                     | _   | _                                 | -                                       | _  | -                                    | -                                    | _                            | -  | +   | _  |
| Provide details<br>on the<br>performed<br>study selection<br>process/flow<br>chart                        | _                                 | +                                     | +                                     | _   | +                                 | +                                       | +  | +                                    | +                                    | +                            | +  | +   | +  |

| Report included study characteristics   | - | + | + | + | + | + | + | + | + | + | +  | +           | +          |
|---|---|---|---|---|---|---|---|---|---|---|----|-------------|------------|
| Provide data of<br>the selected<br>studies on the<br>outcome<br>measures of<br>interest | + | + | + | + | + | + | + | + | + | + | +  | +           | +          |
| Data were extracted by more than 1 reviewer   | ? | + | + |   | + | + | ? | + | + | + | +  | +           | +          |
| Contacted<br>authors for<br>additional<br>information                                   | + | ? | + | + | ? | ? | ? | ? | ? | ? | ?  | ?           | +          |
| Report<br>heterogeneity<br>of the included<br>studies                                   | _ | + | + | + | + | + | + | + | + | + | +  | +           | +          |
| Estimated risk of<br>bias in<br>individual<br>studies                                   | - | + | + | _ | + | + | + | + | + | + | +  | +           | +          |
| Performed a meta-analysis   | + | _ | + | + | + | _ | _ | + | + | + | +  | +           | +          |
| Performed a<br>descriptive<br>analysis  | - | + | + | + | + | + | + | _ | + | + | +  | +           | +          |
|   |   |   |   |   |   |   |   |   |   |   | (c | ontinued or | next page) |

| Table 2<br>(continued)   |                                   |                                       |                                       |   |                                   |   |  |                                      |                                      |                              |                              |   |  |
|--|-----------------------------------|---------------------------------------|---------------------------------------|---|-----------------------------------|---|--|--------------------------------------|--------------------------------------|------------------------------|------------------------------|---|--|
| Author,<br>Criteria  | Addy et al, <sup>25</sup><br>2007 | Afennich et al, <sup>27</sup><br>2010 | Berchier et al, <sup>32</sup><br>2010 | Gunsolley, <sup>23,24</sup><br>2006, 2010 | Haps et al, <sup>33</sup><br>2008 | Hossainian et al, <sup>28</sup><br>2011 | Paraskevas &<br>van der Weijden, <sup>35</sup><br>2006 | Serrano et al, <sup>26</sup><br>2015 | Stoeken et al, <sup>34</sup><br>2007 | Van Leeuwen et al,³¹<br>2011 | Van Leeuwen et al,³0<br>2014 | Van Maanen-<br>Schakel et al, <sup>29</sup><br>2012 | Van Strydonck et al, <sup>18</sup><br>2012 |
| Described additional subanalyses                               | +                                 | +                                     | +                                     | _   | +                                 | +                                       |  | +                                    | +                                    | +                            | _                            | +   | +  |
| Grading of the obtained evidence                               | _                                 | _                                     | _                                     | _   |                                   | _                                       | _  |                                      | _                                    | _                            | +                            | +   | +  |
| Present<br>limitations of<br>the systematic<br>review          | -                                 | _                                     | _                                     | _   | _                                 | +                                       | +  | +                                    | +                                    | -                            | +                            | +   | +  |
| Provide a<br>conclusion<br>that respond<br>to the<br>objective | +                                 | +                                     | +                                     | +   | +                                 | +                                       | +  | +                                    | +                                    | +                            | +                            | +   | +  |

| Publication bias assessed                    | -           | _        | _        | _           | _        | _        | _        | +   | _   | _        | +        | +        | +      |
|--|-------------|----------|----------|-------------|----------|----------|----------|-----|-----|----------|----------|----------|--------|
| Funding source                               | _           | +        | +        | +           | _        | +        | _        | +   | +   | +        | +        | +        | +      |
| Conflict of interest statement               | +           | +        | +        | _           | -        | +        | -        | +   | +   | +        | +        | +        | +      |
| Original authors estimated level of evidence | NR          | NR       | NR       | NR          | NR       | NR       | NR       | NR  | NR  | NR       | Moderate | Moderate | Strong |
| Current authors estimated quality score      | 52%         | 74%      | 78%      | 52%         | 70%      | 78%      | 63%      | 85% | 81% | 78%      | 85%      | 93%      | 89%    |
| Current authors<br>estimated risk<br>of bias | Substantial | Moderate | Moderate | Substantial | Moderate | Moderate | Moderate | Low | Low | Moderate | Low      | Low      | Low    |

Each of the above items of the reporting and methodological quality item score list was given a rating of a plus (+) for informative description of the item at issue and a study design meeting the quality standard was assigned, plus-minus (±) was assigned if the item was incompletely described, ? when unknown, and minus (–) was used if the item was not described at all.<sup>19</sup>

For the quality assessment score, individual items with a positive rating were summed to obtain an overall percentage score. *Abbreviations:* f.i; for instance; NR, not reported.

|                       | Source  | : reviews regarding plaque index so |                                  | utcomes                                |                         | Heter              | ogeneity              |
|-----------------------|---|-------------------------------------|----------------------------------|--|-------------------------|--------------------|-----------------------|
|                       | Systematic Reviews  | No. Experiments Included in MA      | Difference of Means              | 95% CI                                 | P                       | l <sup>2</sup> , % | <u> </u>              |
| ALX                   | Serrano et al, <sup>26</sup> 2015   | 2                                   | -0.16                            | −0.25 to −0.08                         | <.0001                  | 39.5               | ns                    |
| СРС                   | Gunsolley, <sup>24</sup> 2006<br>Haps et al, <sup>33</sup> 2008<br>Serrano et al, <sup>26</sup> 2015          | 7<br>7<br>10                        | -15.4%<br>-0.35<br>-0.39         | []<br>-0.47 to -0.24<br>-0.54 to -0.24 |                         | []<br>71.6<br>93.9 | []<br>.002<br>.000    |
| CHX                   | Gunsolley, <sup>24</sup> 2006<br>Van Strydonck et al, <sup>18</sup> 2012<br>Serrano et al, <sup>26</sup> 2015 | 6<br>5<br>3                         | -40.4%<br>-0.68<br>-0.64         | []<br>-0.85 to -0.51<br>-0.76 to -0.52 | []<br><.00001<br><.0001 | []<br>60.0<br>47.4 | []<br>.06<br>ns       |
| DEL                   | Addy et al, <sup>25</sup> 2007<br>Serrano et al, <sup>26</sup> 2015   | 8<br>3                              | -0.34<br>-0.14                   | -0.39 to -0.29<br>-0.23 to -0.06       | <.00001<br>.001         | []<br>0            | []<br>ns              |
| EO                    | Gunsolley, <sup>24</sup> 2006<br>Stoeken et al, <sup>34</sup> 2007<br>Serrano et al, <sup>26</sup> 2015       | 25<br>7<br>9                        | - <b>27.0%</b><br>-0.83<br>-0.83 | []<br>-1.13 to -0.53<br>-1.05 to -0.60 | []<br>.00001<br>.000    | []<br>96.1<br>97.0 | []<br><.00001<br>.000 |
| HEX                   | Afennich et al, <sup>27</sup> 2011  | 0                                   | []                               | []                                     | []                      | []                 | []                    |
| OA                    | Hossainian et al, <sup>28</sup> 2011  | 0                                   | []                               | []                                     | []                      | []                 | []                    |
| SAN                   | Serrano et al, <sup>26</sup> 2015   | 1                                   | -12.1%                           | []                                     | []                      | []                 | []                    |
| SnF <sub>2</sub>      | Paraskevas & van der<br>Weijden, <sup>35</sup> 2006   | []                                  |                                  |  | []                      | []                 | []                    |
|                       | Serrano et al, <sup>26</sup> 2015   | 2                                   | -0.08                            | -0.26 to 0.10                          | ns                      | 60.9               | ns                    |
| TCL                   | Serrano et al, <sup>26</sup> 2015   | 3                                   | -0.68                            | -0.85 to -0.51                         | <.0001                  | 68.0               | .04                   |
| 0.12% CHX vs 0.2% CHX | Berchier et al, <sup>32</sup> 2010  | 9                                   | -0.10                            | −0.17 to −0.03                         | .008                    | 0                  | ns                    |
| EO vs CHX             | Van Leeuwen et al,31 2011   | 5                                   | -0.19                            | −0.30 to −0.08                         | <.0009                  | 0                  | ns                    |
| OA plus CHX           | Van Maanen-Schakel<br>et al, <sup>29</sup> 2012   | 3                                   | -0.10                            | −0.17 to −0.04                         | .003                    | 0                  | .97                   |

Abbreviations: [], no data available; ALX, alexidine; CHX, chlorhexidine; CPC, cetylpyridinium chloride; DEL, delmopinol; EO, essential oils; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; HEX, hexetidine; MA, meta analyzis; OA, oxygenating agents; SAN, sanguinarine; SnF<sub>2</sub>, stannous fluoride; TCL, triclosan.

<sup>&</sup>lt;sup>a</sup> P>.1 is not significant (NS).

|                       | Source  |                                | Oı                       | utcomes                                |                         | Hetero             | ogeneity        |
|-----------------------|---|--------------------------------|--------------------------|--|-------------------------|--------------------|-----------------|
| Ingredient            | Systematic Reviews  | No. Experiments Included in MA | Difference of Means      | 95% CI                                 | P                       | l <sup>2</sup> , % | <b>P</b> a      |
| ALX                   | Serrano et al, <sup>26</sup> 2015   | 1                              | -0.09                    | -024 to 0.07                           | ns                      | []                 | []              |
| CPC                   | Gunsolley, <sup>24</sup> 2006   | 6                              | -13.4%                   | []                                     | []                      | []                 | []              |
|                       | Haps et al, <sup>33</sup> 2008<br>Serrano et al, <sup>26</sup> 2015                                     | 7<br>4                         | −0.15<br>−0.33           | -0.23 to -0.07<br>-0.53 to -0.12       | .0003<br>.002           | 87.0<br>95.3       | <.0001<br>.000  |
| CHX                   | Gunsolley, <sup>24</sup> 2006   | 6                              | -28.7%                   | []                                     | []                      | []                 | []              |
|                       | Van Strydonck et al, <sup>18</sup> 2012<br>Serrano et al, <sup>26</sup> 2015                            | 3<br>6                         | −0.24<br>−0.17           | -0.29 to -0.20<br>-0.25 to -0.08       | <.0001<br><.0001        | 87.0<br>59.5       | .0005<br>.03    |
| DEL                   |   |                                | []                       | []                                     | []                      | <br>[]             | <br>[]          |
| EO                    | Gunsolley, <sup>24</sup> 2006<br>Stoeken et al, <sup>34</sup> 2007<br>Serrano et al, <sup>26</sup> 2015 | 24<br>8<br>2                   | -18.2%<br>-0.14<br>-0.13 | []<br>-0.25 to -0.03<br>-0.19 to -0.07 | []<br><.00001<br><.0001 | []<br>75.4<br>45.1 | []<br>.02<br>ns |
| HEX                   | Affenich et al, <sup>27</sup> 2011  | []                             | []                       | []                                     | []                      | []                 | []              |
| OA                    | Hossainian et al, <sup>28</sup> 2011  | []                             | []                       | []                                     | []                      | []                 | []              |
| SAN                   | Serrano et al, <sup>26</sup> 2015   | 1                              | -2.8%                    | []                                     | []                      | []                 | []              |
| SnF <sub>2</sub>      | Paraskevas & van der<br>Weijden, <sup>35</sup> 2006   | []                             | []                       | []                                     | []                      | []                 | []              |
|                       | Serrano et al, <sup>26</sup> 2015   | 2                              | -0.25                    | −0.43 to −0.07                         | .007                    | 54.2               | ns              |
| TCL                   | Serrano et al, <sup>26</sup> 2015   | 3                              | -0.27                    | −0.31 to −0.24                         | <.0001                  | 41.0               | ns              |
| 0.12% CHX vs 0.2% CHX | Berchier et al, <sup>32</sup> 2010  | []                             | []                       | []                                     | []                      | []                 | []              |
| EO vs CHX             | Van Leeuwen et al,31 2011   | 4                              | -0.03                    | -0.16 to 0.09                          | ns                      | 62.0               | .05             |
| OA plus CHX           | Van Maanen-Schakel<br>et al, <sup>29</sup> 2012   | []                             | []                       | []                                     | []                      | []                 | []              |

Abbreviations: [], no data available; ALX, alexidine; CHX, chlorhexidine; CPC, cetylpyridinium chloride; DEL, delmopinol; EO, essential oils; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; HEX, hexetidine; MA, meta analyzis; OA, oxygenating agents; SAN, sanguinarine; SnF<sub>2</sub>, stannous fluoride; TCL, triclosan.

<sup>&</sup>lt;sup>a</sup> P>.1 is not significant (NS).

the Gingival Index ( $Gl^{37}$ ) were based on one study and showed a nonsignificant mean difference of -0.09 as compared with the control group.

# Cetylpyridinium chloride

Cetylpyridinium chloride (CPC) is a cationic quaternary ammonium compound with surface-active properties. Its mechanism of action relies on the hydrophilic part of the CPC molecule interacting with the bacterial cell membrane leading to loss of cell components, disruption of cell metabolism, inhibition of cell growth, and finally cell death. It has a broad antimicrobial spectrum, with rapid killing of gram-positive pathogens and yeast in particular. CPC may cause brown staining of teeth. The search retrieved 3 systematic reviews concerning the efficacy of CPC evaluating the adjunctive effect to toothbrushing in the prevention of plaque accumulation and gingival inflammation. The systematic review by Gunsolley<sup>23,24</sup> identified 7 articles in studies with a duration of 6 months or longer. The study outcome with respect to the PI at the finish of the individual studies demonstrated a weighted mean percentage reduction of 15.4% (SD 7.6). Data with respect to the GI showed weighted mean percentage reduction of 13.4% (SD 8.7).

The systematic review by Haps and colleagues<sup>33</sup> identified 8 articles in studies of 4 or more weeks' duration. The meta-analysis of PI scores at the end of the individual studies demonstrated a significant DiffM of -0.35, with moderate heterogeneity ( $I^2 = 71.6\%$ ). Data with respect to the GI showed a significant DiffM of -0.15 in favor of CPC as compared with the control group (considerable heterogeneity,  $I^2 = 87\%$ ). The most recent systematic review by Serrano and colleagues<sup>26</sup> identified 10 articles in studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.39, with considerable heterogeneity ( $I^2 = 93.9\%$ ). Data with respect to the GI showed a significant DiffM of -0.33 in favor of CPC as compared with the control group (considerable heterogeneity,  $I^2 = 95.3\%$ ).

#### Chlorhexidine

Chlorhexidine (CHX) is a cationic bisbiguanide that is active against gram-positive and gram-negative organisms, facultative anaerobes, aerobes, and yeasts. CHX lasts longer in the mouth than other mouthwashes (substantivity) and can cause stains on teeth, tongue, gingiva, and resin restorations. Prolonged use also can reduce bitter and salty taste sensations. CHX was first investigated more than 50 years ago and is currently one of the most widely used and thoroughly evaluated oral topical antiseptics.

The search retrieved 3 systematic reviews concerning the efficacy of CHX evaluating the adjunctive effect against toothbrushing in the prevention of plaque accumulation and gingival inflammation. The systematic review by Gunsolley<sup>23,24</sup> identified 6 articles in studies of 6 or more months' duration. The study outcome with respect to the PI at the finish of the individual studies demonstrated a weighted mean percentage reduction of 40.4% (SD 11.5). Data with respect to the GI<sup>37</sup> showed weighted mean percentage reduction of 28.7% (SD 6.5).

The systematic review by Van Strydonck and colleagues<sup>18</sup> identified 30 articles and evaluated the adjunctive effect of CHX to toothbrushing in the prevention of plaque accumulation and gingival inflammation in patients with gingivitis, including studies of 4 or more weeks' duration.

The meta-analysis of PI scores at the finish of the individual studies considered by the authors to be at "low risk" demonstrated a DiffM of -0.68, heterogeneity was not significant ( $I^2 = 60\%$ ). Data with respect to the GI showed a DiffM of -0.24, in favor of

CHX as compared with the control rinse (considerable heterogeneity,  $I^2 = 87\%$ ). Relative to control, the reduction with CHX for plaque was calculated to be 33% and for gingivitis 26%. The CHX rinsing groups demonstrated significantly more staining.

The most recent systematic review by Serrano and colleagues<sup>26</sup> identified 14 articles in studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.64, with nonsignificant heterogeneity ( $I^2 = 47.4\%$ ). Data with respect to the GI showed a significant DiffM of -0.17, in favor of CHX as compared with the control group (considerable heterogeneity,  $I^2 = 95.3\%$ ).

# Delmopinol

Delmopinol, an amino alcohol, is a third-generation antiplaque agent used as a mouthwash to reduce plaque and alleviate gingivitis. It has surface-active properties and creates an environment that will not allow plaque biofilm and bacteria to adhere.

The search retrieved 2 systematic reviews concerning the efficacy of CHX evaluating the adjunctive effect to toothbrushing in the prevention of plaque accumulation and gingival inflammation. The systematic review by Addy and colleagues<sup>25</sup> identified 8 studies with durations ranging from 8 to 24 weeks. Analyses for plaque and gingivitis based on aggregated data confirm the efficacy of delmopinol 0.2% over the placebo for PI scores, demonstrating a significant DiffM of -0.34. Data with respect to the GI were not available. Modified gingival index<sup>38</sup> scores and bleeding on probing (BOP) scores also showed a significant effect on gingivitis. Analysis also revealed no sustained heterogeneity of outcome, although the variable of BOP ranged considerably across the studies from less than 10% to greater than 30% (DiffM -2.8%).

The most recent systematic review by Serrano and colleagues<sup>26</sup> identified 3 articles in studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.14, with nonsignificant heterogeneity ( $I^2 = 0\%$ ). Data with respect to the GI were not available. Modified  $GI^{38}$  scores and BOP scores indicate a nonsignificant effect on gingivitis.

#### Essential oils

Essential oils (EOs) are used in an over-the-counter mouthwash containing a fixed formula of 2 phenol-related EOs, thymol 0.064% and eucalyptol 0.092%, mixed with menthol 0.042% and methyl salicylate 0.060% in a 22% alcohol vehicle. The antimicrobial mechanisms of action of EO against bacteria are complex. At high concentrations, there is disruption of the cell wall and precipitation of cell proteins, whereas at lower concentrations, there is inactivation of essential enzymes. Also, antinflammatory action has been proposed based on antioxidant activity. EOs also may cause staining of teeth.<sup>39,40</sup> The search retrieved 3 systematic reviews concerning the efficacy of EO evaluating the adjunctive effect to toothbrushing in the prevention of plaque accumulation and gingival inflammation. The systematic review by Gunsolley<sup>23,24</sup> identified 20 articles with a study duration of 6 or more months including unpublished data. The study outcome with respect to the PI at the finish of the individual studies demonstrated a weighted mean percentage reduction of 27% (SD 11.0). Data with respect to the GI showed weighted mean percentage reduction of 18.2% (SD 9.0).

The systematic review by Stoeken and colleagues<sup>34</sup> identified 11 studies with durations of 6 or more months. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.83, with considerable heterogeneity ( $I^2 = 96.1\%$ ). Data with respect to the (modified) GI showed a

significant DiffM of -0.14 in favor of CHX as compared with the control group (moderate heterogeneity,  $I^2=75.4\%$ ). The most recent systematic review by Serrano and colleagues<sup>26</sup> identified 15 articles including studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.14, with nonsignificant heterogeneity ( $I^2=0\%$ ). Data with respect to the GI showed a significant (P<.0001) DiffM of -0.13 in favor of CHX as compared with the control group (nonsignificant heterogeneity,  $I^2=45.1\%$ ). Differences in modified GI scores also were significant and more pronounced (DiffM -0.54, 95% CI -0.76 to -0.31).

#### Hexetidine

Hexetidine (HEX) belongs to the group of pyrimidine derivatives. It is a broad-spectrum antiseptic, active in vitro and in vivo against gram-positive and gram-negative bacteria as well as yeast. However, oral retention appears to be limited so that the antimicrobial activity does not last long. The systematic review by Afennich and colleagues<sup>27</sup> identified 6 articles and evaluated the adjunctive effect of HEX to toothbrushing in the prevention of plaque accumulation and gingival inflammation in short-term ( $\leq$ 4 weeks) and long-term ( $\geq$ 4 weeks) study designs. The data that were retrieved did not allow for a meta-analysis. Therefore, a descriptive analysis was presented that showed that both in the short and long term, antiplaque effects can be expected; however, no concomitant effect on GI scores was observed.

#### Oxygenating agents

Oxygenating agents (OAs), such as hydrogen peroxide ( $H_2O_2$ ), buffered sodium peroxyborate, and peroxycarbonate, have been recommended for short-term use as disinfectants. They exert antimicrobial effects through the release of oxygen. The systematic review by Hossainian and colleagues<sup>28</sup> identified 10 articles and evaluated the adjunctive effect of OA to toothbrushing in the prevention of plaque accumulation and gingival inflammation in short-term ( $\leq 4$  weeks) and long-term ( $\geq 4$  weeks) study designs. The data that were retrieved did not allow for a meta-analysis. Therefore, a descriptive analysis was presented that showed that OA mouthwashes do not consistently prevent plaque accumulation when used as a short-term monotherapy. When used as a long-term adjunct to daily oral hygiene, the results of one study indicate that OA mouthwash reduces gingival redness.

#### Sanguinarine

Sanguinarine (SAN) is a (toxic) quaternary ammonium salt from the group of benzyli-soquinoline alkaloids. It is extracted from some plants, including bloodroot (Sanguinaria canadensis). It is also found in the root, stem, and leaves of the opium poppy. The systematic review by Serrano and colleagues<sup>26</sup> identified 1 article evaluating the adjunctive effect of SAN to toothbrushing in the prevention of plaque accumulation and gingival inflammation with 6 months' duration. The study outcome with respect to the PI at the finish of the study demonstrated a significant mean difference of 12.1% versus placebo and data with respect to the GI showed a nonsignificant mean difference of 2.8%.

#### Stannous fluoride

Tin fluoride, commonly referred to commercially as stannous fluoride ( $SnF_2$ ) is a well-known agent that has been used in dentifrice formulations as early as the beginning of the 1940s. Apart from reducing the incidence of dental caries, it has antimicrobial effects and as such has been formulated in mouthwashes. The combination of tin and fluoride is difficult to formulate because of limited stability in an aqueous solution.

 ${\rm SnF_2}$  may cause a yellowish-brown staining of teeth. The search retrieved 2 systematic reviews concerning the efficacy of  ${\rm SnF_2}$  evaluating the adjunctive effect to tooth-brushing in the prevention of plaque accumulation and gingival inflammation. The systematic review by Paraskevas and van der Weijden<sup>35</sup> identified 2 articles evaluating mouthwashes in studies with a duration of 6 or more months. The data that were retrieved did not allow for a meta-analysis. Therefore, a descriptive analysis was presented that showed that  ${\rm SnF_2}$  mouthwashes do not consistently prevent plaque accumulation or prevent gingivitis. The most recent systematic review by Serrano and colleagues<sup>26</sup> identified 3 articles in studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a nonsignificant DiffM of -0.08, with nonsignificant heterogeneity ( ${\rm I}^2=60.9\%$ ). Data with respect to the GI showed a significant DiffM of -0.25 in favor of CHX as compared with the control group (nonsignificant heterogeneity,  ${\rm I}^2=54.2\%$ ).

#### Triclosan

Triclosan (TCL) is a nonionic chlorinated aromatic compound that has functional groups representative of both ethers and phenols. It has antibacterial and antifungal properties and is applied in consumer products, including soaps and detergents. In mouthwash products it is combined with either zinc sulfate or a copolymer. The systematic review by Serrano and colleagues<sup>26</sup> identified 4 articles that evaluated the adjunctive effect of TCL as pre-rinse to toothbrushing in the prevention of plaque accumulation and gingival inflammation in studies of 6 or more months' duration. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a significant DiffM of -0.68, with moderate heterogeneity ( $I^2 = 68\%$ ). Data with respect to GI showed a significant DiffM of -0.27 in favor of TCL as compared with the control group (nonsignificant heterogeneity,  $I^2 = 41.0\%$ ).

#### **Comparisons of Active Ingredients**

#### Chlorhexidine 0.12% versus chlorhexidine 0.2%

In their systematic review, Berchier and colleagues<sup>32</sup> identified 8 articles evaluating the 2 CHX concentrations in relation to the prevention of plaque accumulation and gingival inflammation with no limits to study duration. With respect to the PI scores at the finish of the individual studies demonstrated a significant (P = .008) DiffM of -0.10 (95% CI -0.17 to -0.03), in favor of 0.2% CHX with nonsignificant heterogeneity ( $I^2 = 0\%$ ). The investigators considered the clinical relevance of this difference likely to be negligible. Information concerning the effect on gingival inflammation was sparse. Descriptive analysis tended to show that there was no difference.

# Essential oils versus chlorhexidine

The systematic review by Van Leeuwen and colleagues<sup>31</sup> identified 19 articles that evaluated the adjunctive effect of EO mouthwash against CHX in short-term ( $\leq$ 4 weeks) and long-term ( $\geq$ 4 weeks) study designs. Long-term studies evaluating the adjunctive effect to toothbrushing showed that, at the end of the studies, PI scores were reduced significantly (P<.0009) with DiffM of -0.19 (95% CI -0.30 to -0.08), in favor of CHX as compared with the EO group with nonsignificant heterogeneity ( $I^2 = 0\%$ ). Data with respect to GI showed a nonsignificant DiffM of -0.03 (95% CI -0.16–0.09) with moderate heterogeneity ( $I^2 = 62\%$ , P = .05).

#### Essential oil versus alcohol solution

The systematic review by Van Leeuwen and colleagues<sup>30</sup> identified 5 articles that evaluated the adjunctive effect of EO mouthwash against an alcohol vehicle solution of 21.6 or 26.9% hydro-alcohol (V-Sol) in short-term (<4 weeks) and long-term

( $\geq$ 4 weeks) study designs. Long-term studies evaluating the adjunctive effect to tooth-brushing showed with respect to the PI scores at the finish of the individual studies a significant (P<.00001) DiffM of -0.39 (95% CI -0.47 to -0.30), in favor of EO with nonsignificant heterogeneity ( $I^2 = 0\%$ ). Data with respect to GI showed, in favor of EO, a significant (P<.00001) DiffM of -0.36 (95% CI -0.62 to -0.26), with considerable heterogeneity ( $I^2 = 92\%$ , P<.00004).

#### Hexetidine versus chlorhexidine

In their systematic review Afennich and colleagues<sup>27</sup> (see earlier in this article) showed in their descriptive analysis that HEX is consistently less effective in plaque reduction than a CHX mouthwash and also less effective in reducing gingival inflammation than a CHX mouthwash.

# Oxygenating agents versus chlorhexidine

In their systematic review, Hossainian and colleagues<sup>28</sup> (see earlier in this article) showed in their descriptive analysis that OAs are consistently less effective in plaque reduction than a CHX mouthwash.

# Combination of Active Ingredients

# Chlorhexidine and oxygenating agents

In their systematic review, Van Maanen-Schakel and colleagues dentified 4 articles that evaluated the adjunctive effect of OA in combination with CHX in relation to the prevention of plaque accumulation and gingival inflammation with no limits to study duration. In their descriptive analysis, CHX in combination with OA showed no consistent difference in plaque or gingivitis reduction as compared with CHX mouthwash alone. Meta-analysis concerning the Silness and Löe PI (1964) showed a significant DiffM in favor of the combination (DiffM  $-0.10,\,95\%$  CI -0.17 to -0.04) with nonsignificant heterogeneity (I² = 0%). However, a significant (P = .02) reduction in staining was observed in the combination with OA (DiffM  $-0.27,\,95\%$  CI -0.49 to -0.05]), with nonsignificant heterogeneity (I² = 38%, P = .20).

#### Evidence Profile

Table 5 shows a summary of the various factors used to rate the body of evidence and strength of recommendations according to GRADE. There is strong evidence in support of the efficacy of both CHX and EO that have a large beneficial effect on plaque reduction and a moderate effect on gingivitis. There is also strong evidence in support of the efficacy of CPC, which has a moderate beneficial effect on both plaque and gingivitis scores. There is moderate evidence for a small effect of ALX and for a large effect of TCL when used as pre-rinse before toothbrushing. Weak evidence emerged for small or indistinct effects of HEX, OA, SAN, and SnF<sub>2</sub>.

#### DISCUSSION

This meta-review summarized the available evidence as was present in the form of systematic reviews with respect to the efficacy of mouthwash for plaque control in managing gingivitis. We included only systematic reviews because there are many such reviews available and this type of research generally provides more evidence than separate empirical studies taken alone. There was strong consistent evidence emerging from 3 systematic reviews that evaluated CHX and EO showing that these ingredients are effective in plaque reduction. However, the evidence also shows moderate to considerable heterogeneity in the meta-analysis. In cases in which heterogeneity is obvious, readers should exercise caution, as the DiffM may not provide an

| Table 5<br>Estimated evidence   | e profile <sup>21</sup> foi   | r the effect of v             | various active i              | ngredients of                 | mouthwashes                   | on dental pla                 | aque and ging                 | jival health                  |                               |                               |
|---|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| GRADE   | ALX                           | СРС                           | СНХ                           | DEL                           | EO                            | HEX                           | OA                            | SAN                           | SnF <sub>2</sub>              | TCL                           |
| Study Designs   | Systematic<br>Review<br>n = 1 | Systematic<br>Review<br>n = 3 | Systematic<br>Review<br>n = 3 | Systematic<br>Review<br>n = 2 | Systematic<br>Review<br>n = 3 | Systematic<br>Review<br>n = 1 | Systematic<br>Review<br>n = 1 | Systematic<br>Review<br>n = 1 | Systematic<br>Review<br>n = 2 | Systematic<br>Review<br>n = 1 |
| Reporting and<br>methodological<br>estimated<br>potential risk<br>of bias | Low                           | Low to<br>Substantial         | Low to<br>Substantial         | Substantial                   | Low to<br>Substantial         | Moderate                      | Moderate                      | Low                           | Low to<br>Moderate            | Low                           |
| Consistency   | Inconsistent                  | Consistent                    | Consistent                    | Fairly consistent             | Consistent                    | Inconsistent                  | Inconsistent                  | Inconsistent                  | Inconsistent                  | Consistent                    |
| Heterogeneity   | ND                            | Considerable                  | Considerable                  | ND                            | Considerable                  | ND                            | ND                            | ND                            | Moderate                      | Moderate                      |
| Directness  | Direct                        | Direct                        | Direct                        | Direct                        | Direct                        | Indirect                      | Indirect                      | Direct                        | Direct                        | Indirect                      |
| Precision   | Precise                       | Precise                       | Precise                       | Imprecise                     | Precise                       | Imprecise                     | Imprecise                     | Imprecise                     | Imprecise                     | Precise                       |
| Publication bias  | Possible                      |
| Magnitude of the effect   | Small                         | Moderate                      | Large                         | Small                         | Large                         | Indistinct                    | Indistinct                    | Small                         | Small                         | large                         |
| Body of evidence  | Moderate                      | Strong                        | Strong                        | Weak                          | Strong                        | Weak                          | Weak                          | Weak                          | Weak                          | Moderate                      |

Abbreviations: ALX, alexidine; CHX, chlorhexidine; CPC, cetylpyridinium chloride; DEL, delmopinol; EO, essential oils; HEX, hexetidine; ND, not determinable; OA, oxygenating agents; SAN, sanguinarine; SnF<sub>2</sub>, tin (stannous) fluoride; TCL, triclosan.

exact measure of the results. It is therefore difficult to compare these 2 chemical agents based on the DiffM or make inferences that one ingredient would be more effective than the other. Only one review emerged that compared mouthwash ingredients<sup>31</sup> with a moderate estimated risk of bias and a quality score of 78%. It showed that in comparison to EO, CHX provided better results for plaque control. For the long-term control of gingival inflammation, EO was not different from CHX.

# Grading

The steps toward guideline development involve formulating recommendations that clinicians and their patients should follow. 41 A variety of systems are used to rate the quality of the evidence underlying their recommendations. The GRADE working group has developed a common, sensible, and transparent approach to grading quality of evidence and strength of recommendations. Many international organizations have provided input into the development of the approach and have started using it. The strength of a recommendation indicates the extent to which one can be confident that the desirable effects of an intervention outweigh its undesirable effects. When a recommendation is weak, clinicians and other health care providers need to devote more time to the process of shared decision-making by which they ensure that the informed choice reflects individual values and preferences. This is likely to involve ensuring patients understand the implications of the choices they are making, possibly by using a formal decision aid. When recommendations are strong, clinicians may spend less time on the process of making a decision, and focus efforts on overcoming barriers to implementation or adherence. However, the strength of a recommendation may not be directly correlated with its priority for implementation.<sup>42</sup> Alternatively, in considering 2 or more possible management strategies, a recommendation's strength represents the confidence that the net benefit clearly favors one alternative or another. From this meta-review, 2 chemical agents emerged for which strong evidence with a large effect was available to recommend their use in mouthwash products. These were CHX and EO.

#### Side Effects

Various side effects have been reported for mouthwash products of which staining is a more common complaint following use of CHX, CPC, delmopinol (DEL) EO, and SnF<sub>2</sub>. The staining can become worse when other products that are known to cause staining, such as tea, coffee, wine, and cigarettes, are consumed at the same time. One systematic review included in this meta-analysis showed that there is moderate evidence that a combination of CHX and an OA reduces tooth staining and also showed that it slightly but significantly increases inhibition of plaque growth.<sup>29</sup> Another issue is taste disturbance, which has been attributed to CHX, CPC, DEL EO, SAN, and HEX. For instance CHX, which tastes bitter, greatly reduces the perceived intensity of the salt.<sup>43</sup> The development of taste disturbance and tooth staining and the promotion of calculus formation does not permit the widespread long-term use of CHX as a daily adjunct to normal oral hygiene procedures. 18 CHX is therefore rather restricted to short-term to moderate-term use and in special clinical situations. A rare side effect that can be disturbing to the patient is parotid swelling, which has been reported after the use of both HEX and CHX.44 The investigators of this case report concluded that parotid swelling may not be related to the type of mouthwash used, but may instead be a consequence of the rinsing action itself. Another potential adverse effect is a shift in the type or quantity of oral commensals. Virtually all of the main chemical plaquecontrol agents do not produce major shifts or development of resistant strains. When, on rare occasion, adverse effects on the oral microflora emerge, these effects

quickly disappear when the chemical is discontinued.<sup>8,45</sup> Tissue disturbance has been reported for SAN, which is suspect for causing the formation of white lesions.<sup>46</sup> Although the available clinical and animal data provide no support that the use of a SAN mouthwash is causally associated,<sup>47</sup> its production has been discontinued.<sup>48</sup>

# Chlorhexidine and sodium lauryl sulfate

Chemicals in mouthwash and dentifrice formulations can result in antagonism with reduction or negation of activity of one or both chemicals. In the broad search, 2 systematic reviews surfaced concerning the negative impact dentifrices containing sodium lauryl sulfate (SLS) may have on the efficacy of CHX mouthwash on the prevention of plague accumulation and gingival inflammation. This interaction is not restricted to just CHX but any cationic antiseptic-containing mouthwash, such as CPC, making it essential that active mouthwash ingredients are evaluated for bioavailability under normal use. SLS is the most commonly used surfactant in dentifrices that, in addition to other properties, enhance the dentifrice foaming action. In their systematic review Kolahi and Soolari<sup>49</sup> identified an unclear number of articles that evaluated the effect of SLS in combination with CHX in relation to the prevention of plaque accumulation and gingival inflammation with no limits to study duration. There was not sufficient similarity between the included trails to combine them in a formal metaanalysis. Hence, the investigators declare that they used best evidence synthesis as an intelligent alternative for meta-analysis. They concluded that there are adequate reasons to believe CHX and SLS dentifrices are not compatible. Also, besides SLS, CHX may not be compatible with many anionic compounds found in dentifrices.<sup>50</sup>

More recently, Elkerbout and colleagues  $^{51}$  also evaluated the effect of SLS in combination with CHX in relation to the prevention of plaque accumulation and gingival inflammation with no limits to study duration and identified 4 articles. The study outcome with respect to the PI scores at the finish of the individual studies demonstrated a nonsignificant DiffM of -0.08 (95% CI -0.26–0.11), with nonsignificant heterogeneity ( $I^2 = 0\%$ ). No analysis with respect to gingivitis scores could be performed. The investigators concluded that there is moderate evidence to state that SLS dentifrice can be freely used in combination with CHX. Van Strydonck and colleagues  $I^{18}$  also noted that in most of the studies in their review CHX was always combined with regular oral hygiene procedures. However, this usage still showed a beneficial effect on oral health, which indicates that the impact of SLS may not be clinically relevant.

# Substantivity and bioavailability

Mouthwashes are simply a means for delivery of active substances in the oral cavity where, after 20 to 30 seconds of rinsing, all surfaces of the dentition have come into contact with the mouthwash.<sup>52</sup> Most are composed of a water or water-alcohol base, with flavor, surfactant, and humectant added for their cosmetic properties. Mouthwashes and their active ingredients are exposed to the mouth for a relatively short period of time before expectoration from the mouth. In addition, the proteins present in saliva may reduce the activity of some substances.<sup>53</sup> The property of substantivity ensures that, at least for some chemicals (such as CHX), possible antibacterial effects are sustained for much longer periods of time.<sup>45</sup> Substantivity refers to the ability of an agent to be retained in the oral cavity and to be released over an extended period of time with retention of potency. The overall oral retention of an antiplaque agent is determined by the strength and rate of association of the agent with its receptor sites and the accessibility of these sites. The substantivity of an antiplaque agent and its clearance from the oral cavity are determined by the rate of dissociation of the agent from the receptor sites and the salivary composition and flow rate.<sup>9</sup> CHX is well

known for its substantivity being retained in supragingival plaque, the tooth pellicle, and the oral soft tissues from where it exerts a plaque inhibitory effect that, within the oral cavity, may last up to 12 hours.<sup>54</sup>

It is noteworthy that the inclusion of a known active agent in a formulation does not guarantee efficacy, although it is often used to make piggy-back claims for new products. For instance, 2 recent systematic reviews have shown that CHX can be successfully formulated into a dentifrice/gel and will inhibit plaque growth to some degree, but not to the same extent as CHX incorporated into a mouthwash. 55,56 Many oral hygiene products are complex formulations, and the potential for ingredient interactions is great. Bioavailability is an issue that deserves attention when formulating a mouthwash. Formulations with high bioavailable CPC are associated with greater biological activity and therefore suggest an increased probability for clinical efficiency. 57

#### Alcohol

Alcohol in mouthwashes is used to enhance flavor impact, to solubilize the flavor and some active ingredients, to provide some preservative power, and improve the transport of active ingredients into the dental plaque biofilm. The systematic review by Van Leeuwen and colleagues<sup>30</sup> indicated that the alcohol vehicle solution does not contribute to the efficacy of the mouthwash. Although the accumulated effects of mouthrinse usage with a high percentage of alcohol and ingestion of alcohol could theoretically predispose toward oral or pharyngeal carcinoma, the contributory effects of alcohol in these rinses are unclear and not considered proven<sup>58</sup> by most national regulatory organizations, including the US Food and Drug Administration.<sup>59</sup>

More recently, for various reasons, there has been an increase in the demand for alcohol-free mouthwashes.  $^{60}$  An important determination is whether the inclusion or exclusion of alcohol could affect the activity of the mouthwashes. In the meta-analysis of Serrano and colleagues,  $^{26}$  10 studies evaluating EO included 9 mouthwash products that contained alcohol and 1 that did not. Based on this limited evidence, no major difference was observed (DiffM for alcohol -0.827 and mean difference alcohol free -0.746). Berchier and colleagues,  $^{32}$  in their 0.12% versus 0.2% CHX article, performed a subanalysis on 0.12% CHX with/without alcohol as compared with 0.2% CHX with alcohol. The data show a trend that the nonalcohol product was slightly less effective.

There has been concern that alcohol from mouthwash products is being converted to acetaldehyde in the oral cavity, which then may cause DNA damage and lead to mutations. A meta-analysis of epidemiologic studies concerning mouthwash and oral cancer also specifically evaluating mouthwash products containing greater than 25% alcohol was performed by Gandini and colleagues. <sup>61</sup> The meta-analysis included 18 studies. No statistically significant associations (relative risk [RR]) were found between regular use of mouthwash and risk of oral cancer (RR 1.13; 95% CI 0.95–1.35). There was also no association reported use of mouthwash specifically containing alcohol and risk of oral cancer (RR 1.16; 95% CI 0.44–3.08). Based on their observations, the investigators came to the conclusion that based on the quantitative analysis of mouthwash use and oral malignancy, no statistically significant associations were revealed between mouthwash use and risk of oral cancer, nor was any significant trend observed in risk with increasing daily use, nor association between use of mouthwash containing alcohol and oral cancer risk.

#### Rinse Duration and Volume

The manufacturers of mouthwash products recommend different durations for the rinsing procedure. Keijser and colleagues<sup>62</sup> compared mouthwashes with various

rinsing times. Results of the questionnaire indicated that the subjects preferred the shorter rinsing time, which raises the question of whether shorter rinsing times can be sufficient for effective plague control. Another study assessed the plagueinhibiting effect of a 0.2% CHX solution with 3 different rinsing times following a 72-hour nonbrushing period, this being 60 seconds as proposed by the manufacturer, and 2 shorter rinsing times of 30 seconds and 15 seconds. 63 The outcome did not reveal a significant difference in plaque development whether the subjects rinsed for 60, 30, or 15 seconds, which suggests that even 15 seconds may be long enough to reduce plaque levels. Berchier and colleagues<sup>32</sup> also showed that there is minimal difference between rinsing for 30 or 60 seconds on plaque scores. Further studies are needed to establish whether shorter rinsing times will be sufficient for effective gingivitis control. A consideration is that a shorter rinsing time could have a positive effect on compliance. Manufacturers also recommend different volumes, ranging from 10 to 20 mL. It seems relevant to have information about the mouthwash volume that is understood by the patient to ensure optimal compliance. One study assessed the volume of mouthwash with respect to patients' perceptions of comfort.<sup>64</sup> This study investigated volunteers' subjective perceptions to different volumes of mouthwash (volumes of 5, 10, 15, 20, and 30 mL) to establish the most comfortable volume of mouthwash with which to rinse. Based on the results of this experiment with a nonfoaming mouthwash, it was concluded that the most pleasant volume of mouthwash is 15 mL. This volume had a mean visual analogue scale (VAS) score that was closest to the optimal score. The differences between the mean VAS scores of rinsing with 15 mL and other volumes were statistically significant (P<.001).

# Limitations of mouthwashes in the prevention of dental plaque formation

- The oral biofilm produces an encased and highly protective community of cells that acts as a barrier and as a result is much less influenced by its environment, including the introduction of chemical agents.<sup>65</sup> This aspect has received little attention in mouthwash studies.
- There appears to be a consensus that mouthwashes with antiplaque agents are not designed to be used in isolation and should be used in combination with mechanical cleaning.<sup>8</sup>
- For individuals with existing disease with frank periodontal pocketing, the use of vehicles such as mouthwash or dentifrice to deliver antimicrobial and antiplaque agents has only limited or no effects on the subgingival flora.<sup>8,45</sup> In these cases, chemical agents need to be placed directly into the subgingival environment by subgingival irrigation or by some alternative drug-release device. However, within minutes, gingival crevicular fluid outflow will dilute subgingivally applied antiseptics.<sup>66</sup>
- Only sparse information is available with respect to the efficacy of chemotherapeutic agents on biofilm-contaminated titanium surfaces.<sup>67</sup>
- Mouthwashes can also act as a vehicle in which to incorporate chemicals that
  promote fresh breath and help alleviate the problem of oral malodor. This aspect
  was not addressed by this meta-analysis. Systematic reviews have shown that
  due to very limited evidence, the potential effect of a specifically formulated
  mouthwash for treating oral malodor is, in general, unclear.<sup>68,69</sup>
- Publication bias cannot be ruled out. The results as presented in this meta-review
  may therefore provide a biased estimate of the true effect (overestimation)
  because there is a tendency to publish mainly positive studies.

#### Cost-effectiveness

The long-term adjunctive use of antiplaque agents in any vehicle other than dentifrice would have significant cost implications to the average family. At present prices, the cost of mouthwashes would be far greater than that of toothbrushes and dentifrice. This may be prohibitive for many individuals, and dentifrice is thus still the best vehicle for delivering antiplaque agents. Nonetheless, if a mouthwash is highly effective in terms of oral health gain, the additional cost of its use may be a price worth paying. As emerged out of this review, this would apply particularly to CHX and EO mouthwashes.

#### **SUMMARY**

This meta-review summarized and appraised the current state of evidence based on systematic reviews, with respect to the efficacy of various active ingredients of over-the-counter chemotherapeutic mouthwash formulations for plaque control in managing gingivitis. Evidence suggests that a mouthwash containing CHX is the first choice. The most reliable alternative for plaque control is EO. No difference between CHX and EO with respect to gingivitis was observed.

#### **ACKNOWLEDGMENTS**

Because this is a synopsis of earlier work, parts of this article have been published before and therefore some duplication is inevitable. The authors thank Spiros Paraskevas for providing additional data concerning Stoeken and colleagues.<sup>34</sup>

#### **REFERENCES**

- 1. Axelsson P, Nyström B, Lindhe J. The long-term effect of a plaque control program on tooth mortality, caries and periodontal disease in adults. Results after 3 years of maintenance. J Clin Periodontol 2004;31:749–57.
- Sälzer S, Slot DE, Van der Weijden FA, et al. Efficacy of inter-dental mechanical plaque control in managing gingivitis—a meta-review. J Clin Periodontol 2015; 42:S92–105.
- 3. Van der Weijden FA, Slot DE. Efficacy of homecare regimens for mechanical plaque removal in managing gingivitis: a meta review. J Clin Periodontol 2015;42:S77–91.
- 4. Van der Weijden F, Slot DE. Oral hygiene in the prevention of periodontal diseases: the evidence. Periodontol 2000 2011;55:104–23.
- Löe H, Theilade E, Jensen SB. Experimental gingivitis in man. J Periodontol 1965; 36:177–87.
- Weinberger B. Introduction to the history of dentistry. St Louis (MO): Mosby; 1948.
- Jackson RJ. Metal salts, essential oils and phenols-old or new? Periodontol 2000 1997;15:63-73.
- 8. Moran JM. Chemical plaque control–prevention for the masses. Periodontol 2000 1997;15:109–17.
- 9. Cummins D, Creeth JE. Delivery of antiplaque agents from dentifrices, gels, and mouthwashes. J Dent Res 1992;71(7):1439–49.
- 10. Cummins D. Vehicles: how to deliver the goods. Periodontol 2000 1997;15:84–99.
- 11. Suvan JE, D'Aiuto F. Progressive, paralyzed, protected, perplexed? What are we doing? Int J Dent Hyg 2008;6:251–2.

- 12. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
- 13. Dicenso A, Bayley L, Haynes RB. Accessing pre-appraised evidence: fine-tuning the 5S model into a 6S model. Evid Based Nurs 2009;12(4):99–101.
- 14. Smith V, Devane D, Begley CM, et al. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011:11:15–21.
- Francke AL, Smit MC, de Veer AJ, et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 2008;12:38.
- **16.** Sarrami-Foroushani P, Travaglia J, Debono D, et al. Scoping meta-review: introducing a new methodology. Clin Transl Sci 2015;8:77–81.
- 17. AMSTAR tool 2007. A measurement tool to assess systematic reviews. Available at: http://amstar.ca/index.php. Accessed April 30, 2015.
- 18. Van Strydonck DA, Slot DE, Van der Velden U, et al. Effect of a chlorhexidine mouthrinse on plaque, gingival inflammation and staining in gingivitis patients: a systematic review. J Clin Periodontol 2012;39:1042–55 [studies selected for this meta-review].
- 19. PRISMA statement, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Available at: http://www.prismastatement.org/. Accessed April 30, 2015.
- Hidding JT, Beurskens CH, van der Wees PJ, et al. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One 2014;9:e96748.
- 21. GRADE Working Group. Grading of recommendations assessment, development and evaluation. 2011. Available at: <a href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</a>. Accessed April 30, 2015.
- 22. Chen Y, Wong RW, McGrath C, et al. Natural compounds containing mouthrinses in the management of dental plaque and gingivitis: a systematic review. Clin Oral Investig 2014;18:1–16.
- 23. Gunsolley JC. Clinical efficacy of antimicrobial mouthrinses. J Dent 2010;38: S6–10 [studies selected for this meta-review].
- 24. Gunsolley JC. A meta-analysis of six-month studies of antiplaque and antigingivitis agents. J Am Dent Assoc 2006;137:1649–57 [studies selected for this meta-review].
- 25. Addy M, Moran J, Newcombe RG. Meta-analyses of studies of 0.2% delmopinol mouth rinse as an adjunct to gingival health and plaque control measures. J Clin Periodontol 2007;34:58–65 [studies selected for this meta-review].
- 26. Serrano J, Escribano M, Roldán S, et al. Efficacy of adjunctive anti-plaque chemical agents in managing gingivitis: a systematic review and meta-analysis. J Clin Periodontol 2015;42:S106–38 [studies selected for this meta-review].
- 27. Afennich F, Slot DE, Hossainian N, et al. The effect of hexetidine mouthwash on the prevention of plaque and gingival inflammation: a systematic review. Int J Dent Hyg 2011;9:182–90 [studies selected for this meta-review].
- 28. Hossainian N, Slot DE, Afennich F, et al. The effects of hydrogen peroxide mouthwashes on the prevention of plaque and gingival inflammation: a systematic review. Int J Dent Hyg 2011;9:171–81 [studies selected for this meta-review].
- 29. Van Maanen-Schakel NW, Slot DE, Bakker EW, et al. The effect of an oxygenating agent on chlorhexidine-induced extrinsic tooth staining: a systematic review. Int J Dent Hyg 2012;10:198–208 [studies selected for this meta-review].

- 30. Van Leeuwen MP, Slot DE, Van der Weijden GA. The effect of an essential-oils mouthrinse as compared to a vehicle solution on plaque and gingival inflammation: a systematic review and meta-analysis. Int J Dent Hyg 2014;12:160–7 [studies selected for this meta-review].
- 31. Van Leeuwen MP, Slot DE, Van der Weijden GA. Essential oils compared to chlorhexidine with respect to plaque and parameters of gingival inflammation: a systematic review. J Periodontol 2011;82:174–94 [studies selected for this meta-review].
- 32. Berchier CE, Slot DE, Van der Weijden GA. The efficacy of 0.12% chlorhexidine mouthrinse compared with 0.2% on plaque accumulation and periodontal parameters: a systematic review. J Clin Periodontol 2010;37:829–39 [studies selected for this meta-review].
- 33. Haps S, Slot DE, Berchier CE, et al. The effect of cetylpyridinium chloride-containing mouth rinses as adjuncts to toothbrushing on plaque and parameters of gingival inflammation: a systematic review. Int J Dent Hyg 2008;6:290–303 [studies selected for this meta-review].
- 34. Stoeken JE, Paraskevas S, van der Weijden GA. The long-term effect of a mouthrinse containing essential oils on dental plaque and gingivitis: a systematic review. J Periodontol 2007;78:1218–28 [studies selected for this meta-review].
- 35. Paraskevas S, van der Weijden GA. A review of the effects of stannous fluoride on gingivitis. J Clin Periodontol 2006;33:1–13 [studies selected for this meta-review].
- **36.** Quigley GA, Hein JW. Comparative cleansing efficiency of manual and power brushing. J Am Dent Assoc 1962;65:26–9.
- 37. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963;21:533–51.
- 38. Lobene RR. A clinical study of the anticalculus effect of a dentifrice containing soluble pyrophosphate and sodium fluoride. Clin Prev Dent 1986;8:5–7.
- 39. Addy M, Moran J, Newcombe R, et al. The comparative tea staining potential of phenolic, chlorhexidine and anti-adhesive mouthrinses. J Clin Periodontol 1995; 22:923–8.
- 40. Grossman E, Meckel AH, Isaacs RL, et al. A clinical comparison of antibacterial mouthrinses: effects of chlorhexidine, phenolics, and sanguinarine on dental plaque and gingivitis. J Periodontol 1989;60:435–40.
- 41. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008;337:a744.
- 42. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719–25.
- 43. Frank ME, Gent JF, Hettinger TP. Effects of chlorhexidine on human taste perception. Physiol Behav 2001;74:85–99.
- 44. Van der Weijden GA, Ten Heggeler JM, Slot DE, et al. Parotid gland swelling following mouthrinse use. Int J Dent Hyg 2010;8:276–9.
- 45. Moran JM. Home-use oral hygiene products: mouthrinses. Periodontol 2000 2008;48:42–53.
- 46. Mascarenhas AK, Allen CM, Loudon J. The association between Viadent use and oral leukoplakia. Epidemiology 2001;12:741–3.
- 47. Munro IC, Delzell ES, Nestmann ER, et al. Viadent usage and oral leukoplakia: a spurious association. Regul Toxicol Pharmacol 1999;30:182–96.
- **48.** Vlachojannis C, Magora F, Chrubasik S. Rise and fall of oral health products with Canadian bloodroot extract. Phytother Res 2012;26:1423–6.
- 49. Kolahi J, Soolari A. Rinsing with chlorhexidine gluconate solution after brushing and flossing teeth: a systematic review of effectiveness. Quintessence Int 2006;37:605–12.

- 50. Sweetman SC, editor. Martindale: the complete drug reference. 33rd edition. London: PhP Pharmaceutical Press; 2002. p. 1138–40.
- 51. Elkerbout TA, Slot DE, Bakker E, et al. Chlorhexidine mouthwash and sodium lauryl sulphate dentifrice: do they mix effectively or interfere? Int J Dent Hyg 2015. [Epub ahead of print].
- 52. Paraskevas S, Danser MM, Timmerman MF, et al. Optimal rinsing time for intraoral distribution (spread) of mouthwashes. J Clin Periodontol 2005;32:665–9.
- 53. Asadoorian J. Canadian Dental Hygienists Association position paper on commercially available, over-the-counter oral rinsing products. Can J Dent Hyg 2006;40(4):1–13.
- 54. Tomás I, Cousido MC, García-Caballero L, et al. Substantivity of a single chlor-hexidine mouthwash on salivary flora: influence of intrinsic and extrinsic factors. J Dent 2010;38:541–6.
- 55. Slot DE, Berchier CE, Addy M, et al. The efficacy of chlorhexidine dentifrice or gel on plaque, clinical parameters of gingival inflammation and tooth discoloration: a systematic review. Int J Dent Hyg 2014;12:25–35.
- 56. Supranoto SC, Slot DE, Addy M, et al. The effect of chlorhexidine dentifrice or gel versus chlorhexidine mouthwash on plaque, gingivitis, bleeding and tooth discoloration: a systematic review. Int J Dent Hyg 2015:13:83–92.
- 57. Versteeg PA, Rosema NA, Hoenderdos NL, et al. The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model – a cross-over study. Int J Dent Hyg 2010;8:269–75.
- 58. Elmore JG, Horowitz RI. Oral cancer and mouthwash use: evaluation of the epidemiological evidence. Otolaryngol Head Neck Surg 1995;113:253–61.
- 59. FDA. Oral health care drug products for over-the-counter human use: tentative final monograph for oral antiseptic drug products. Fed Regist 1994;59:6084–124.
- 60. Pereira EM, da Silva JL, Silva FF, et al. Clinical evidence of the efficacy of a mouthwash containing propolis for the control of plaque and gingivitis: a phase II study. Evid Based Complement Alternat Med 2011;2011:750249.
- 61. Gandini S, Negri E, Boffetta P, et al. Mouthwash and oral cancer risk quantitative meta-analysis of epidemiologic studies. Ann Agric Environ Med 2012;19:173–80.
- 62. Keijser JA, Verkade H, Timmerman MF, et al. Comparison of 2 commercially available chlorhexidine mouthrinses. J Periodontol 2003;74:214–8.
- 63. Van der Weijden GA, Timmerman MF, Novotny AG, et al. Three different rinsing times and inhibition of plaque accumulation with chlorhexidine. J Clin Periodontol 2005;32:89–92.
- 64. Keukenmeester RS, Slot DE, Rosema NA, et al. Determination of a comfortable volume of mouthwash for rinsing. Int J Dent Hyg 2012;10:169–74.
- 65. Auschill TM, Hein N, Hellwig E, et al. Effect of two antimicrobial agents on early in situ biofilm formation. J Clin Periodontol 2005;32(2):147–52.
- 66. Binder TA, Goodson JM, Socransky SS. Gingival fluid levels of acid and alkaline phosphatase. J Periodontal Res 1987;22:14–9.
- 67. Ntrouka VI, Slot DE, Louropoulou A, et al. The effect of chemotherapeutic agents on contaminated titanium surfaces: a systematic review. Clin Oral Implants Res 2011;22:681–90.
- 68. Blom T, Slot DE, Quirynen M, et al. The effect of mouthrinses on oral malodor: a systematic review. Int J Dent Hyg 2012;10:209–22.
- 69. Slot DE, De Geest S, van der Weijden FA, et al. Treatment of oral malodour. Medium-term efficacy of mechanical and/or chemical agents: a systematic review. J Clin Periodontol 2015;42:S303–16.